You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
山東新華製藥股份(00719.HK)A股異動 擬與拜耳醫藥保健在健康消費品領域開展合作

格隆匯11月9日丨山東新華製藥股份(00719.HK)公吿,公司2022年11月8日、11月9日A股股票連續兩個交易日收盤價格漲幅偏離值累計達到20%,根據深圳證券交易所的有關規定,屬於股票交易異常波動的情況。

針對公司股票異常波動,公司對有關事項進行了核查,有關情況説明如下:

1、經核查,公司前期披露的信息不存在需要更正、補充處。

2、近期公共傳媒未報道可能或已經對公司股票交易價格產生較大影響的未公開重大信息。

3、近期公司經營情況及內外部經營環境未發生重大變化。

4、2022年10月20日公司披露了《關於呋塞米注射液(2ml:20mg)通過仿製藥一致性評價的公吿》及《關於潑尼松龍獲得化學原料藥上市申請批准通知書的公吿》。

5、2022年10月26日公司披露了《2022年三季度報吿》。

6、2022年11月3日公司披露了《關於全資子公司獲得〈藥品補充申請批准通知書〉等相關情況的公吿》。

7、公司日前與拜耳醫藥保健有限公司簽訂了《戰略合作備忘錄》,雙方致力於充分發揮各自優勢,結合雙方企業自身業務特點,整合彼此優勢資源,擬在健康消費品領域開展深度戰略合作。雙方願意通過致力於新品研發、深度拓展電商領域等合作,共同推動構建醫藥保健新格局,以期為中國消費者提供更多更好的醫藥健康產品和選擇,為消費者提供更精準更個性化的服務。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account